PDGFRβ moves to melanoma cells via exosomal transport and activates the phosphatidylinositol-3-kinase (PI3K-AKT) signaling pathway, thereby reducing the susceptibility to BRAF inhibitors [39]. Here, BRAF is linked to melanoma.